Teppei Hagino

Inzai, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 94 publications

Routine blood biomarkers associated with clinical response to tralokinumab in patients with atopic dermatitis: a 48-week real-world study in Japan.

Routine blood biomarkers associated with clinical response to tralokinumab in patients with atopic dermatitis: a 48-week real-world study in Japan.

Journal: European journal of dermatology : EJD

Published: September 05, 2026

Systemic Treatment of Psoriasis: Current Evidence on Efficacy and Safety.

Systemic Treatment of Psoriasis: Current Evidence on Efficacy and Safety.

Journal: The Journal of dermatology

Published: June 14, 2026

Effectiveness, biomarker transition, and safety of 48-week tralokinumab treatment for atopic dermatitis: real-world analyses stratified by age groups (15-17, 18-64, and ≥ 65 years).

Effectiveness, biomarker transition, and safety of 48-week tralokinumab treatment for atopic dermatitis: real-world analyses stratified by age groups (15-17, 18-64, and ≥ 65 years).

Journal: European journal of dermatology : EJD

Published: May 25, 2026

Real-World Effectiveness of Tildrakizumab in Japanese Patients With Psoriasis: Analyses Stratified by Prior Systemic Therapy, Maintenance of Early Responses, and Achievement of Delayed Responses.

Real-World Effectiveness of Tildrakizumab in Japanese Patients With Psoriasis: Analyses Stratified by Prior Systemic Therapy, Maintenance of Early Responses, and Achievement of Delayed Responses.

Journal: The Journal of dermatology

Published: May 21, 2026

Letter: Long-Term Safety and Effectiveness of Lebrikizumab Treatment for Moderate-to-Severe Atopic Dermatitis Stratified by Age Groups in Real-World Clinical Practice in Japan.

Letter: Long-Term Safety and Effectiveness of Lebrikizumab Treatment for Moderate-to-Severe Atopic Dermatitis Stratified by Age Groups in Real-World Clinical Practice in Japan.

Journal: Dermatitis : contact, atopic, occupational, drug

Published: March 02, 2026

Effectiveness of Lebrikizumab Treatment for Patients with Atopic Dermatitis Switched from Dupilumab or Tralokinumab: A 48-Week Real-World Retrospective Study.

Effectiveness of Lebrikizumab Treatment for Patients with Atopic Dermatitis Switched from Dupilumab or Tralokinumab: A 48-Week Real-World Retrospective Study.

Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Published: February 23, 2026

Sustainability of Early Responses and Achievement of Delayed Responses to Lebrikizumab in Atopic Dermatitis: A 48-Week Japanese Real-World Study.

Sustainability of Early Responses and Achievement of Delayed Responses to Lebrikizumab in Atopic Dermatitis: A 48-Week Japanese Real-World Study.

Journal: Dermatitis : contact, atopic, occupational, drug

Published: February 06, 2026

Real-World Effectiveness of Lebrikizumab for the Prurigo Nodularis-Like Phenotype of Atopic Dermatitis: A One-Year Retrospective Study.

Real-World Effectiveness of Lebrikizumab for the Prurigo Nodularis-Like Phenotype of Atopic Dermatitis: A One-Year Retrospective Study.

Journal: Journal of drugs in dermatology : JDD

Published: February 05, 2026

Long-term outcomes after switching from baricitinib 4 mg to upadacitinib 30 mg in atopic dermatitis: A 144-week retrospective study.

Long-term outcomes after switching from baricitinib 4 mg to upadacitinib 30 mg in atopic dermatitis: A 144-week retrospective study.

Journal: Journal of the American Academy of Dermatology

Published: January 19, 2026

Seventy-Two-Week Real-World Outcomes of Tralokinumab Treatment for Moderate-To-Severe Atopic Dermatitis: Analyses Stratified by Baseline Rash and Itch Severity.

Seventy-Two-Week Real-World Outcomes of Tralokinumab Treatment for Moderate-To-Severe Atopic Dermatitis: Analyses Stratified by Baseline Rash and Itch Severity.

Journal: The Journal of dermatology

Published: January 16, 2026

Three-year real-world outcomes of upadacitinib treatment for atopic dermatitis: Systemic therapy-naïve versus -experienced patients.

Three-year real-world outcomes of upadacitinib treatment for atopic dermatitis: Systemic therapy-naïve versus -experienced patients.

Journal: Journal of the American Academy of Dermatology

Published: January 05, 2026

Effectiveness of Apremilast in Patients With Palmoplantar Pustulosis: A 28-Week Real-World Study.

Effectiveness of Apremilast in Patients With Palmoplantar Pustulosis: A 28-Week Real-World Study.

Journal: The Journal of dermatology

Published: January 02, 2026

Showing 1-12 of 94

Last Updated: 09/26/2026